Clinical Trials
22
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (21 trials with phase data)• Click on a phase to view related trials
Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers
- Conditions
- CancerHLA-A*02:01-positive
- Interventions
- Drug: Chemotherapy drugDrug: Kinase inhibitorDrug: Antiangiogenic AgentDrug: Monoclonal antibody
- First Posted Date
- 2025-02-21
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Immunocore Ltd
- Target Recruit Count
- 600
- Registration Number
- NCT06840119
- Locations
- 🇩🇪
Universitaetsklinikum Heidelberg, Heidelberg, Germany
🇮🇹Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy
🇮🇹nstituto Clinico Humanitas, Rozzano, Italy
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
- Conditions
- Advanced Melanoma
- Interventions
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Immunocore Ltd
- Target Recruit Count
- 680
- Registration Number
- NCT06112314
- Locations
- 🇺🇸
University of Arizona, Tucson, Arizona, United States
🇺🇸University of California - San Diego, La Jolla, California, United States
🇺🇸The Angeles Clinic and Research Institute- West Los Angeles, Los Angeles, California, United States
Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection
- Conditions
- Hepatitis B, Chronic
- Interventions
- Drug: IMC-I109V Multiple Ascending DosesDrug: IMC-I109V Single Ascending DoseDrug: HBV HCC Module MAD
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Immunocore Ltd
- Target Recruit Count
- 180
- Registration Number
- NCT05867056
- Locations
- 🇺🇸
University of Southern California Keck School of Medicine, Los Angeles, California, United States
🇺🇸University Hospitals Cleveland Medical Center Case Western Reserve, Cleveland, Ohio, United States
🇦🇺St. Vincent's Hospital, Fitzroy, Australia
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
- Conditions
- Advanced Melanoma
- Interventions
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2025-07-23
- Lead Sponsor
- Immunocore Ltd
- Target Recruit Count
- 540
- Registration Number
- NCT05549297
- Locations
- 🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸University of Kansas Cancer Center - Westwood, Westwood, Kansas, United States
🇦🇹LKH - Universitaetsklinikum Graz, Graz, Austria
A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp
- Conditions
- Uveal Melanoma
- First Posted Date
- 2021-07-14
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- Immunocore Ltd
- Registration Number
- NCT04960891
- Prev
- 1
- 2
- 3
- Next